CN101522707B - 肌肉生长抑制素拮抗剂 - Google Patents

肌肉生长抑制素拮抗剂 Download PDF

Info

Publication number
CN101522707B
CN101522707B CN2007800366228A CN200780036622A CN101522707B CN 101522707 B CN101522707 B CN 101522707B CN 2007800366228 A CN2007800366228 A CN 2007800366228A CN 200780036622 A CN200780036622 A CN 200780036622A CN 101522707 B CN101522707 B CN 101522707B
Authority
CN
China
Prior art keywords
myostatin
muscle
polypeptide
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800366228A
Other languages
English (en)
Chinese (zh)
Other versions
CN101522707A (zh
Inventor
拉维·坎巴德
姆里杜拉·沙玛
莫妮卡·S·S·德穆拉
卡罗尔·J·贝里
维多利亚·赛里特
罗伯特·S·鲍尔
吉纳·D·尼古拉斯
克雷格·D·麦克法莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myopharm Ltd
Original Assignee
Moyostin Medical Co ltd
Orico Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moyostin Medical Co ltd, Orico Ltd filed Critical Moyostin Medical Co ltd
Publication of CN101522707A publication Critical patent/CN101522707A/zh
Application granted granted Critical
Publication of CN101522707B publication Critical patent/CN101522707B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
CN2007800366228A 2006-08-03 2007-08-02 肌肉生长抑制素拮抗剂 Expired - Fee Related CN101522707B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83552506P 2006-08-03 2006-08-03
US60/835,525 2006-08-03
PCT/NZ2007/000203 WO2008016314A1 (en) 2006-08-03 2007-08-02 Myostatin antagonists

Publications (2)

Publication Number Publication Date
CN101522707A CN101522707A (zh) 2009-09-02
CN101522707B true CN101522707B (zh) 2013-08-28

Family

ID=38997428

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800366228A Expired - Fee Related CN101522707B (zh) 2006-08-03 2007-08-02 肌肉生长抑制素拮抗剂

Country Status (9)

Country Link
US (1) US8309068B2 (enExample)
EP (1) EP2054434B1 (enExample)
JP (3) JP2009545313A (enExample)
CN (1) CN101522707B (enExample)
AU (1) AU2007279456A1 (enExample)
BR (1) BRPI0715072A2 (enExample)
CA (1) CA2693378C (enExample)
DK (1) DK2054434T3 (enExample)
WO (1) WO2008016314A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI649332B (zh) 2018-03-21 2019-02-01 英屬安圭拉商維多利亞生物醫學控股股份有限公司 Composition for promoting local muscle growth, slowing or preventing local muscle atrophy and use thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5335239B2 (ja) * 2004-09-30 2013-11-06 マイオスティン・セラピューティクス・プロプライエタリー・リミテッド ミオスタチンアイソフォーム
NO2424895T3 (enExample) * 2009-04-27 2018-02-03
CN101659700B (zh) * 2009-07-27 2011-11-16 广州罗森生物科技有限公司 一种短肽
KR20120082909A (ko) * 2009-10-01 2012-07-24 코비타 리미티드 합성 마이오스타틴 펩티드 길항제
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
CA2808382A1 (en) * 2010-08-16 2012-02-23 Amgen Inc. Antibodies that bind myostatin, compositions and methods
US8871209B2 (en) 2011-11-14 2014-10-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A
JP6706617B2 (ja) * 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
KR20170135967A (ko) 2015-04-15 2017-12-08 리제너론 파마슈티칼스 인코포레이티드 Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
US10287345B2 (en) 2016-01-08 2019-05-14 Scholar Rock, Inc. Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
US11566047B2 (en) 2016-08-10 2023-01-31 Tokyo University Of Pharmacy & Life Sciences Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof
SI3565592T1 (sl) * 2017-01-06 2023-05-31 Scholar Rock, Inc. Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
US11248044B2 (en) 2018-03-01 2022-02-15 Regeneron Pharmaceuticals, Inc. Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor
US11672845B2 (en) 2018-03-21 2023-06-13 Soulyoung Biotech Co., Ltd. Composition for promoting local muscle growth or slowing down or preventing local muscle atrophy and use thereof
JP7300764B2 (ja) * 2018-07-02 2023-06-30 キュラミス カンパニー・リミテッド 細胞融合技術を用いた遺伝子及び細胞治療剤、並びにその用途
WO2020154034A1 (en) * 2019-01-25 2020-07-30 Children's Medical Center Corporation Compositions and methods for treating muscular dystrophy and related disorders
US20220331290A1 (en) * 2019-09-24 2022-10-20 Myo-Tec-Sci Pharmaceutical composition for preventing or treating sarcopenia, containing unnatural amino acid
AU2021390998A1 (en) * 2020-12-03 2023-06-29 Kyungsangbukdo (Kyungsangbukdo Livestock Research Institute) Transgenic animal having modified myostatin gene
KR20250122524A (ko) 2022-12-22 2025-08-13 스칼러 락, 인크. 미오스타틴 활성화의 선택적이고 강력한 억제 항체
CN120192396A (zh) * 2023-12-21 2025-06-24 江苏省农业科学院 一种肌肉生长抑制素mstn蛋白突变体及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
EE200200025A (et) 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
WO2001053350A1 (en) 2000-01-18 2001-07-26 Agresearch Limited Myostatin and mimetics thereof
AU2003254585A1 (en) 2002-07-24 2004-02-16 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
BR0314270A (pt) 2002-09-16 2005-08-02 Univ Johns Hopkins Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina
NZ529860A (en) * 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
WO2005066204A2 (en) 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
US20060034831A1 (en) * 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Man-Shiow Jiang等.Characterization and identification of the inhibitory domain of GDF-8 propeptide.《Biochemical and Biophysical Research Communications》.2004,第315卷252-531. *
Xiaolei Zhu等.Dominant negative myostatin produces hypertrophy without hyperplasia in muscle.《FEBS Letters》.2000,71-75. *
顾志良.肌肉生长抑制素基因及其功能.《常熟理工学院学报》.2005,第19卷(第4期),66-71. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI649332B (zh) 2018-03-21 2019-02-01 英屬安圭拉商維多利亞生物醫學控股股份有限公司 Composition for promoting local muscle growth, slowing or preventing local muscle atrophy and use thereof

Also Published As

Publication number Publication date
US8309068B2 (en) 2012-11-13
CA2693378A1 (en) 2008-02-07
WO2008016314A1 (en) 2008-02-07
AU2007279456A1 (en) 2008-02-07
EP2054434B1 (en) 2017-03-15
BRPI0715072A2 (pt) 2013-06-25
JP2014057584A (ja) 2014-04-03
JP2016130251A (ja) 2016-07-21
CA2693378C (en) 2020-04-14
EP2054434A4 (en) 2011-07-13
EP2054434A1 (en) 2009-05-06
US20090324590A1 (en) 2009-12-31
JP5993827B2 (ja) 2016-09-14
JP2009545313A (ja) 2009-12-24
CN101522707A (zh) 2009-09-02
DK2054434T3 (en) 2017-07-03

Similar Documents

Publication Publication Date Title
CN101522707B (zh) 肌肉生长抑制素拮抗剂
US20130065820A1 (en) Synthetic myostatin peptide antagonists
US20020147329A1 (en) Method of modulating tissue growth using Frzb protein
CN105828833A (zh) 突变的成纤维细胞生长因子（fgf）1及使用方法
CZ304224B6 (cs) Monoklonální protilátka
CA2340470A1 (en) Leptin-related peptides
US20100105625A1 (en) Product and Methods for Diagnosis and Therapy for Cardiac and Skeletal Muscle Disorders
JP2003526674A (ja) ボンベシン受容体３の使用
US20090118176A1 (en) Stem Cell Factor-Like Protein Scfa1 and Uses Thereof
JP2008526263A (ja) 幹細胞因子様タンパク質をコードするポリヌクレオチド
JP2001516764A (ja) ペルセフィン及び関連成長因子
AU2013231037B2 (en) Myostatin antagonists
JP2002503967A (ja) ヒレグリン様因子
WO2001032197A2 (en) Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders
JP2001524303A (ja) 腎臓上皮細胞に対するインビトロおよびインビボでの増殖促進タンパク質およびペプチド
KR20030081402A (ko) Ｖｅｇｆ-ｘ 또는 그의 길항제에 의한 평활근 세포 증식의조절
AU2004238332A2 (en) Novel fibroblast growth factors and methods of use thereof
HK1156664A (en) Nucleotide and protein sequences of nogo genes and methods based thereon
HK1140493A (en) Nucleotide and protein sequences of nogo genes and methods based thereon
HK1038027B (en) Nucleotide and protein sequences of nogo genes and methods based thereon

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: MDX BIOTECHNOLOGY LTD.

Free format text: FORMER OWNER: KEWEIDA LTD.

Effective date: 20120724

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Victoria, Australia

Applicant after: Moyostin Medical Co.,Ltd.

Address before: Victoria, Australia

Applicant before: MDX biotech Ltd.

Address after: Dunedin, New Zealand

Applicant after: Vinda Co.,Ltd.

Address before: Dunedin

Applicant before: ORICO LTD.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: OVITA LTD. TO: KEWEIDA LTD.

Free format text: CORRECT: APPLICANT; FROM: MDX BIOTECHNOLOGY LTD. TO: MOJORSTIN MEDICAL LTD.

TA01 Transfer of patent application right

Effective date of registration: 20120724

Address after: Victoria, Australia

Applicant after: MDX biotech Ltd.

Address before: Dunedin, New Zealand

Applicant before: Vinda Co.,Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130828

Termination date: 20210802